Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment

  • Dan Călugăru
  • Mihai CălugăruEmail author
Letter to the Editor

Dear Editor:

We would like to address several challenges that have arisen from the study by Karst et al. [1], which are specifically summarized below.

Several pertinent data are missing from the study (Table 1).
Table 1

Missing data from the article by Karst et al. [1]


Duration of the DME before entry into the study after diabetes onset

The proportion of the eyes considered “dry” on optical coherence tomography at the end of the study

Duration of the time period between the prior treatment with anti-VEGF agents/triamcinolone and the index date (the date of the start of the study)

The criteria used to define the clinically significant DME, if it was present in some patients

The prevalence of vitreoretinal interface abnormalities (e.g.,vitreomacular adhesion/traction and epiretinal membranes) at enrollment and at the end of the follow-up period as potential predictors influencing functional and morphologic improvements

The qualitative status of the ganglion cell complex...



All authors have completed and submitted the ICMJE form for disclosure of potential conflicts of interest. No financial disclosures. Both authors (D.C and M.C) were involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.

The authors have full control over the primary data, and they agree to allow Graefe’s Archive for Clinical and Experimental Ophthalmology to review their data if requested.

Compliance with ethical standards

Conflict of interest

All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge, or beliefs) in the subject matter or materials discussed in this manuscript.


  1. 1.
    Karst SG, Lammer J, Mitsch C et al (2018) Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment. Graefes Arch Clin Exp Ophthalmol 256(1):49–58. CrossRefPubMedGoogle Scholar
  2. 2.
    Freund KB, Korobelnik JF, Deveny R et al (2015) Treat-and extend regimens with anti-VEGF agents in retinal diseases. Retina 35:1489–1506CrossRefPubMedGoogle Scholar
  3. 3.
    Gover S, Murthy RK, Brar VS, Chalam KV (2009) Normative data for macular thickness by high-definition spectral-domain optical coherence tomography (Spectralis). Am J Ophthalmol 148:266–271CrossRefGoogle Scholar
  4. 4.
    Călugăru D, Călugăru M (2017) Aflibercept for diabetic macular edema in eyes previously treated with ranibizumab and/or bevacizumab may further improve macular thickness. Ophthalmic Surg Lasers Imaging Retina 48(7):528–529CrossRefPubMedGoogle Scholar
  5. 5.
    Călugăru D, Călugăru M (2016) Conversion to aflibercept after prior anti-VEGF therapy for persistent diabetic macular edema. Am J Ophthalmol 168(2):290–291PubMedGoogle Scholar
  6. 6.
    Călugăru D, Călugăru M (2016) Pro-permeability factors in diabetic macular edema; the diabetic macular edema treated with ozurdex trial. Am J Ophthalmol 170(l):244–245PubMedGoogle Scholar
  7. 7.
    Călugăru D, Călugăru M (2017) Aflibercept in diabetic macular edema: evaluating efficacy as a primary and secondary therapeutic option. Eye 31(2):342CrossRefPubMedGoogle Scholar
  8. 8.
    Călugăru D, Călugăru M (2017) Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 255(7):1451–1452CrossRefPubMedGoogle Scholar
  9. 9.
    Călugăru D, Călugăru M (2016) Long-term efficacy and safety of intravitreal dexamethasone implant for the treatment of diabetic macular edema. Eur J Ophthalmol 26(6):171–172CrossRefGoogle Scholar
  10. 10.
    Călugăru D, Călugăru M (2017) Real-world outcomes of ranibizumab treatment for diabetic macular edema in a United Kingdom National Health Service setting. Am J Ophthalmol 174(2):175–176Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of OphthalmologyUniversity of MedicineCluj-NapocaRomania

Personalised recommendations